CLINICAL TRIALS PROFILE FOR ENALAPRIL MALEATE
✉ Email this page to a colleague
All Clinical Trials for ENALAPRIL MALEATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000522 ↗ | Treatment of Mild Hypertension Study (TOMHS) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | 1985-08-01 | To compare the effects of nonpharmacologic therapy alone with those of one of five active drug regimens combined with non-pharmacologic therapy, for long- term management of patients with mild hypertension. |
| NCT00000522 ↗ | Treatment of Mild Hypertension Study (TOMHS) | Completed | University of Minnesota | Phase 2 | 1985-08-01 | To compare the effects of nonpharmacologic therapy alone with those of one of five active drug regimens combined with non-pharmacologic therapy, for long- term management of patients with mild hypertension. |
| NCT00000522 ↗ | Treatment of Mild Hypertension Study (TOMHS) | Completed | University of Minnesota - Clinical and Translational Science Institute | Phase 2 | 1985-08-01 | To compare the effects of nonpharmacologic therapy alone with those of one of five active drug regimens combined with non-pharmacologic therapy, for long- term management of patients with mild hypertension. |
| NCT00003070 ↗ | Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer | Completed | National Cancer Institute (NCI) | Phase 3 | 2000-09-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as enalapril, may protect normal cells from the toxic effects of chemotherapy. It is not known whether enalapril is more effective than a placebo in treating heart damage in patients who received anthracycline chemotherapy for childhood cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of enalapril with a placebo in treating heart damage in patients who received anthracycline chemotherapy for childhood cancer. |
| NCT00003070 ↗ | Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer | Completed | Children's Oncology Group | Phase 3 | 2000-09-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as enalapril, may protect normal cells from the toxic effects of chemotherapy. It is not known whether enalapril is more effective than a placebo in treating heart damage in patients who received anthracycline chemotherapy for childhood cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of enalapril with a placebo in treating heart damage in patients who received anthracycline chemotherapy for childhood cancer. |
| NCT00568178 ↗ | An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2)) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2007-06-01 | The purpose of this study is to evaluate the effects of losartan on proteinuria in pediatric patients. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ENALAPRIL MALEATE
Condition Name
Clinical Trial Locations for ENALAPRIL MALEATE
Trials by Country
Clinical Trial Progress for ENALAPRIL MALEATE
Clinical Trial Phase
Clinical Trial Sponsors for ENALAPRIL MALEATE
Sponsor Name
